Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 28 articles: HTML format

Single Articles

January 2023
1. LI Y, Zheng R, Zhang Y, Huang C, et al
   Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.
   Int J Cancer. 2023;152:42-50.
   PubMed     Abstract available
   
   
   December 2022
2. CATTRINI C, Messina C, Mennitto A, Di Maio M, et al
   Comments on "Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)".
   Int J Cancer. 2022;151:2291-2292.
   PubMed    
   
   
   November 2022
3. CHEN HK, Su PJ, Wang YL, Chang KC, et al
   Long Term Use and Risk of Major Adverse Cardiac Events: Comparing Enzalutamide and Abiraterone in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer.
   Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34348.
   PubMed     Abstract available
   
   
   September 2022
4. KRILAVICIUTE A, Albers P, Lakes J, Radtke JP, et al
   Adherence to a risk-adapted screening strategy for prostate cancer - first results of the PROBASE trial.
   Int J Cancer. 2022 Sep 19. doi: 10.1002/ijc.34295.
   PubMed     Abstract available
   
   
   
5. WU J, Tan X
   The role of MTNR1B polymorphism on circadian rhythm-related cancer: A UK Biobank cohort study.
   Int J Cancer. 2022;151:888-896.
   PubMed     Abstract available
   
   
   
6. OLA IO, Talala K, Tammela T, Taari K, et al
   Prostate cancer incidence in men with Prostate-Specific Antigen (PSA) below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC).
   Int J Cancer. 2022 Sep 2. doi: 10.1002/ijc.34274.
   PubMed     Abstract available
   
   
   August 2022
7. JAMES ND, Clarke NW, Cook A, Ali A, et al
   Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
   Int J Cancer. 2022;151:422-434.
   PubMed     Abstract available
   
   
   July 2022
8. CARM KT, Johannessen B, Bogaard M, Bakken AC, et al
   Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer.
   Int J Cancer. 2022 Jul 26. doi: 10.1002/ijc.34226.
   PubMed     Abstract available
   
   
   
9. OSTMAN JR, Pinto RC, Ebbels TM, Thysell E, et al
   Identification of pre-diagnostic metabolites associated with prostate cancer risk by untargeted mass spectrometry-based metabolomics: A case-control study nested in the Northern Sweden Health and Disease Study.
   Int J Cancer. 2022 Jul 22. doi: 10.1002/ijc.34223.
   PubMed     Abstract available
   
   
   
10. GEDEBORG R, Loeb S, Styrke J, Kiiski-Berggren R, et al
    Susceptibility to SARS-Cov-2 Infection and Risk for Severe COVID-19 in Patients with Prostate Cancer on Androgen Deprivation Therapy.
    Int J Cancer. 2022 Jul 8. doi: 10.1002/ijc.34204.
    PubMed     Abstract available
    
    
    June 2022
11. CSIZMARIK A, Keresztes D, Nagy N, Bracht T, et al
    Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
    Int J Cancer. 2022 Jun 11. doi: 10.1002/ijc.34159.
    PubMed     Abstract available
    
    
    May 2022
12. WATTS EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, et al
    Circulating free testosterone and risk of aggressive prostate cancer: prospective and Mendelian randomization analyses in international consortia.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34116.
    PubMed     Abstract available
    
    
    April 2022
13. FORSTER RB, Engeland A, Kvale R, Hjellvik V, et al
    Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in non-metastatic prostate cancer.
    Int J Cancer. 2022 Apr 30. doi: 10.1002/ijc.34058.
    PubMed     Abstract available
    
    
    
14. MATSUSHITA M, Fujita K, Hatano K, Hayashi T, et al
    High-fat diet promotes prostate cancer growth through histamine signaling.
    Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34028.
    PubMed     Abstract available
    
    
    
15. CONTEDUCA V, Scarpi E, Wetterskog D, Brighi N, et al
    Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients.
    Int J Cancer. 2022;150:1166-1173.
    PubMed     Abstract available
    
    
    March 2022
16. DIAZ DE LA GUARDIA-BOLIVAR E, Barrios-Rodriguez R, Zwir I, Jimenez-Moleon JJ, et al
    Identification of novel prostate cancer genes in patients stratified by Gleason classification: role of antitumoral genes.
    Int J Cancer. 2022 Mar 2. doi: 10.1002/ijc.33988.
    PubMed     Abstract available
    
    
    January 2022
17. ARSOV C, Albers P, Herkommer K, Gschwend J, et al
    A Randomized Trial of Risk-Adapted Screening for Prostate Cancer in Young Men - Results of the First Screening Round of the PROBASE Trial.
    Int J Cancer. 2022 Jan 25. doi: 10.1002/ijc.33940.
    PubMed    
    
    
    
18. FAN Z, Ma J, Pan X, Zhao L, et al
    Crosstalk of FGFR1 signaling and choline metabolism promotes cell proliferation and survival in prostate cancer cells.
    Int J Cancer. 2022 Jan 5. doi: 10.1002/ijc.33922.
    PubMed     Abstract available
    
    
    December 2021
19. DJAMGOZ MBA
    Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Int J Cancer. 2021 Dec 2. doi: 10.1002/ijc.33890.
    PubMed    
    
    
    
20. SALMINEN JK, Murtola TJ
    Reply to Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Int J Cancer. 2021 Dec 2. doi: 10.1002/ijc.33887.
    PubMed    
    
    
    October 2021
21. PAYNE H, Robinson A, Rappe B, Hilman S, et al
    A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33845.
    PubMed     Abstract available
    
    
    
22. LI X, Cheng K, Li X, Zhou Y, et al
    Phase I clinical trial of HC-1119: A deuterated form of enzalutamide.
    Int J Cancer. 2021;149:1473-1482.
    PubMed     Abstract available
    
    
    September 2021
23. LIU D, Zhu J, Zhou D, Nikas EG, et al
    A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk.
    Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33808.
    PubMed     Abstract available
    
    
    July 2021
24. KOSTOS L, Hong W, Lee B, Tran B, et al
    Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting.
    Int J Cancer. 2021;149:409-419.
    PubMed     Abstract available
    
    
    April 2021
25. RASPIN K, FitzGerald LM, Marthick JR, Field MA, et al
    A rare variant in EZH2 is associated with prostate cancer risk.
    Int J Cancer. 2021 Apr 6. doi: 10.1002/ijc.33584.
    PubMed     Abstract available
    
    
    February 2021
26. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
    Liquid biopsies: Potential and challenges.
    Int J Cancer. 2021;148:528-545.
    PubMed     Abstract available
    
    
    September 2020
27. WEITZER J, Castano-Vinyals G, Aragones N, Gomez-Acebo I, et al
    Effect of time of day of recreational and household physical activity on prostate and breast cancer risk (MCC-Spain Study).
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33310.
    PubMed     Abstract available
    
    
    August 2020
28. BADRISING SK, Louhanepessy RD, van der Noort V, Coenen JLLM, et al
    A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
    Int J Cancer. 2020;147:1143-1151.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: